Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 192 results for "Tecfidera Treated Patients"

Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme
News-Medical.Net

Over Half of Audited Multiple Sclerosis Patients Currently Tre...

BURLINGTON, Mass. , July 22,2014 /PRNewswire/ --Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing ... OSIX News, 1 week ago
[x]  

3 images for "Tecfidera Treated Patients"

ABC News 4 Charleston, 1 week ago
Global News Canada, 3 months ago
Review Seeker, 4 months ago

Report: Over Half of MS Patients Treated With Tecfidera Have Experienced Minor Side Effects

News Categories Clinical Trials Research News Industry Trends Agency
 Pharmscope1 week ago
American Enterprise Institute

Obamacare drug benefits block access to vital medicines

[description]Many ACA plans have closed drug formularies that exclude some drugs to treat chronic diseases, saddling patients with the full cost of these medications.[/description ] An estimated eight million people have signed up for health care ...
 World Socialist Web Site3 weeks ago Obamacare shortchanges patients with chronic disease  American Enterprise Institute1 month ago Under Obamacare's "Closed Formularies" Patients With Serious Diseases Don't Get Access to Vital And Very Costly Medicines  Forbes.com1 month ago

British Columbia to Reimburse TECFIDERA, a First-Line Oral Treatment for Multiple Sclerosis

/CNW/ - Biogen Idec Canada announces today that TECFIDERA (dimethyl fumarate) is now available for reimbursement in British Columbia (B.C.) through B.C. PharmaCare. TECFIDERA is a first-line oral treatment for adults with relapsing-remitting ...
 CEOWorld Magazine1 month ago
[x]  

Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules

Introduction The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen's Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies.
 Pettinga Financial Advisors1 month ago
[x]  
Motley Fool

Biogen Stock's Tecfidera Embarrasses Wall Street

It's hard to imagine that Biogen Idec (NASDAQ: BIIB Tecfidera was the third oral MS drug to get the FDA green-light when it was approved in March 2013, but while Novartis (NYSE: NVS Another great quarter Biogen's second quarter sales jumped 40% ...
 Motley Fool1 week ago NICE Gives Nod to Biogen Idec's MS Drug Tecfidera  FDA News2 weeks ago Biogen MS blockbuster Tecfidera earns high marks for safety  FiercePharma1 month ago MS Drug Tecfidera More Trouble Than It's Worth?  EMax Health1 month ago
[x]  

Alkermes begins Phase I trial of ALKS 8700 to treat multiple sclerosis

Ireland-based biopharmaceutical firm Alkermes has started a Phase I clinical trial of ALKS 8700, a novel monomethyl fumarate (MMF) molecule being developed for the treatment of multiple sclerosis (MS). The trial will assess the safety, tolerability ...
 Pharmaceutical Business Review1 week ago Alkermes takes its Tecfidera beater into clinical trials for MS  FierceBiotech2 weeks ago
Pharma Letter

NICE issues positive draft FAD guidance on Tecfidera11-07-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has issued the Final Appraisal Determination (FAD) today for US biotech firm Biogen Idec's (Nasdaq: BIIB) new oral multiple sclerosis (MS) drug Tecfidera ...
 Pharma Letter2 weeks ago

MS pill Tecfidera available on NHS in England and Wales

The new MS pill Tecfidera (also known as dimethyl fumarate) has received the final stamp of approval from NICE, and should now be freely available on the NHS in England and Wales to people with active relapsing remitting MS. After an initial ...
 Noodls2 weeks ago
Zacks.com

Pharma, Biotech M&A: Tax Inversion in Focus

Mergers and acquisitions (M&As) continue to play a major role in the pharma sector and are not showing any signs of slowing down. The last few months have brought tax inversion deals into focus considering the number of agreements signed with ...
 Zacks.com1 week ago Pharma, Biotech M&As Heat Up: Tax Inversion in Focus  Yahoo! Finance1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less